| Document Date: 2014-10-01 21:56:22
Open Document File Size: 124,35 KBShare Result on Facebook
Company AEs / Biogen Idec Australia Pty Ltd / Biogen Idec / / Country Australia / / Currency USD / / Event FDA Phase / / Holiday Commonwealth Day / / IndustryTerm magnetic resonance imaging / healthcare costs / MS treatment / fampridine dose / / MedicalCondition usual fatigue / clinically definite multiple sclerosis / headache / acute illness / seizures / self-report disease / urinary tract infection / nausea / cognitive impairment / e.g. insomnia / tremor / pain / progressive / chronic disease / psychiatric disorders / fatigue / injury / multiple sclerosis / greater fatigue / demyelination / mobility dysfunction / dizziness / MS / back pain / / MedicalTreatment physiotherapy / / Movie Quality of Life / / Organization European Medicines Agency / US Food and Drug Administration / FDA / Listing Requested and PBAC’s View Authority / / Person Ann Neurol / / Position model / economic costs / Trial ID/ First author / neurologist / / Product Extended Release Oral / Dalfampridine / F202 / MSF202 / / ProvinceOrState Mississippi / / Technology magnetic resonance imaging / author MS-F202 Protocol / MRI / CGI / /
SocialTag |
Microsoft WordFampridine FAMPYRA Biogen IdecPSD FINAL.doc